Login Register Cart 0
Generic placeholder image

Applied Drug Research, Clinical Trials and Regulatory Affairs

Editor-in-Chief

ISSN (Print): 2667-3371
ISSN (Online): 2667-338X

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Formulation and Development of Nanostructured Lipid Carriers for a Poorly Water-Soluble Drug: Furosemide

Author(s): Abhish B. Jadhav*, Anand D. Savkare and Sachin S. Gaikwad

Volume 9, Issue 1, 2022

Published on: 15 August, 2022

Article ID: e160622206069 Pages: 11

DOI: 10.2174/2667337109666220616103103

Price: $65

Abstract

Aim: Formulation, development and evaluation of solid lipid nanoparticles.

Background: It was found that furosemide (FU) was a very potent drug but it fails to produce bioavailability due to its BCS class IV, so drug- cyclodextrin (CD)- nanostructured lipid carriers (NLC) will be an alternative to improve solubility and permeability as a result of this overall bioavaibility will be improved.

Objective: To improve the solubility of drug by using complexation of cyclodextrin. Coating with the lipids (NLC) will improve the permeability of the drug.

Methods: To generate solid Furosemide-cyclodextrin complexes (FU-CD), two distinct CDs and three different techniques were used. The co-evaporation (COE) Furosemide-β-cyclodextrinloaded NLC (FU- β-CD-COE-loaded NLC) was obtained by emulsification ultrasonic dispersion method. The selected batch was suitably characterized for particle size, polydispersity index, zeta potential, Entrapment efficiency, Drug release study, and permeability study. The crystallization of the drug in the furosemide cyclodextrin complex (FU-CD complex) and the co-evaporation Furosemide- β-cyclodextrin-loaded NLC (FU-β-CD-COE-loaded NLC) was investigated by differential scanning calorimetry (DSC). The in vitro release study was carried out.

Results: The FU-β-CD-COE-loaded NLC and FU-HP-β-CD-COE-loaded NLC (Hydroxypropyl) presented a superior physicochemical property and were selected for further study. The in vitro release study of the above selected batches exhibited a higher dissolution rate in the pH 5.8 phosphate buffer than Furosemide suspension and FU-NLC. The permeability studies of abovementioned batches were compared with FU-Suspension.

Conclusion: The novel formulation considerably enhanced the solubility and permeability of furosemide for oral delivery, and was successfully developed.

Keywords: Furosemide, nano structure lipid carrier, permeability, crystallization, entrapment efficiency, polydispersity index.

Graphical Abstract

[1]
Patel, V.P. In vitro dissolution enhancement of Albendazole by preparation of inclusion complexs with HP-β-cyclodextrin pharma science monitor. Int. J. Pharm. Sci., 2011, 2, 1-11.
[2]
Loftsson, T.; Duchêne, D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm., 2007, 329(1-2), 1-11.
[http://dx.doi.org/10.1016/j.ijpharm.2006.10.044] [PMID: 17137734]
[3]
O’Driscoll, C.M.; Griffin, B.T. Biopharmaceutical challenges associated with drugs with low aqueous solubility-the potential impact of lipid-based formulations. Adv. Drug Deliv. Rev., 2008, 60(6), 617-624.
[http://dx.doi.org/10.1016/j.addr.2007.10.012] [PMID: 18155800]
[4]
Müller, R.H.; Radtke, M.; Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 2002, 242(1-2), 121-128.
[http://dx.doi.org/10.1016/S0378-5173(02)00180-1] [PMID: 12176234]
[5]
Das, S.K. Cyclodextrins- the molecular container. Res. J. Pharm. Biol. Chem. Sci., 2013, 4(21), 694-1699.
[6]
Souto, E.B.; Müller, R.H. Polymorphic behaviour of compritol 888 ATO as bulk lipid and as SLN and NLC. J. Microencapsul., 2016, 23, 377-388.
[http://dx.doi.org/10.1080/02652040500435295] [PMID: 16854814]
[7]
Lin, C.; Chen, F.; Ye, T.; Zhang, L.; Zhang, W.; Liu, D.; Xiong, W.; Yang, X.; Pan, W. A novel oral delivery system consisting in “drug-in cyclodextrin-in nanostructured lipid carriers” for poorly water-soluble drug. Vinpocetine. Int. J. Pharm., 2014, 465(1-2), 90-96.
[http://dx.doi.org/10.1016/j.ijpharm.2014.02.013] [PMID: 24530388]
[8]
Loftsson, T.; Brewster, M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci., 1996, 85(10), 1017-1025.
[http://dx.doi.org/10.1021/js950534b] [PMID: 8897265]
[9]
Luo, Q.; Zhao, J.; Zhang, X.; Pan, W. Nanostructured Lipid Carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int. J. Pharm., 2011, 403(1-2), 185-191.
[http://dx.doi.org/10.1016/j.ijpharm.2010.10.013] [PMID: 20951778]
[10]
Tian, B.; Luo, Q.; Song, S.; Liu, D.; Pan, H.; Zhang, W.; He, L.; Ma, S.; Yang, X.; Pan, W. Novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan for efficient ocular delivery. J. Pharm. Sci., 2012, 101(3), 1040-1049.
[http://dx.doi.org/10.1002/jps.22813] [PMID: 22102480]
[11]
Dollo, G.; Le Corre, P.; Chollet, M.; Chevanne, F.; Bertault, M.; Burgot, J.L.; Le Verge, R. Improvement in solubility and dissolution rate of 1, 2-dithiole-3-thiones upon complexation with beta-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives. J. Pharm. Sci., 1999, 88(9), 889-895.
[http://dx.doi.org/10.1021/js990067o] [PMID: 10479350]
[12]
Patlolla, R.R.; Chougule, M.; Patel, A.R.; Jackson, T.; Tata, P.N.V.; Singh, M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control. Release, 2010, 144(2), 233-241.
[http://dx.doi.org/10.1016/j.jconrel.2010.02.006] [PMID: 20153385]
[13]
Zhuang, C.Y.; Li, N.; Wang, M.; Zhang, X.N.; Pan, W.S.; Peng, J.J.; Pan, Y.S.; Tang, X. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int. J. Pharm., 2010, 394(1-2), 179-185.
[http://dx.doi.org/10.1016/j.ijpharm.2010.05.005] [PMID: 20471464]
[14]
Souto, E.B.; Wissing, S.A.; Barbosa, C.M.; Müller, R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm., 2004, 278(1), 71-77.
[http://dx.doi.org/10.1016/j.ijpharm.2004.02.032] [PMID: 15158950]
[15]
Majahar, S.K. Studies on the preparation characterization and solubility of nimodipine inclusion complexes with β-cyclodextrin. Int. J. Pharma Bio Sci., 2004, 1(2), 1-8.
[16]
Dardeer, H.M. Importance of cyclodextrins into inclusion complexes. Int. J. Adv. Res., 2004, 2(4), 414-428.

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy